Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P.H. Wilding, D.M., Rachel L. Batter ham, M.B., B.S., Ph.D., Salvatore Callanan, Ph.D., Melanie Davies, M.D., Luc F. Van Gaal, M.D., Ph.D., Lidice Lingpa, M.D., M.P.H., M.S.C.S., Barbara M. McGowan, M.D., Ph.D.,
Julio Rosenstock, M.D., Marie T.D. Tran, M.D., Ph.D., Thomas A. Wadden, Ph.D., Sean Wharton, M.D., Pharm.D., Koutaro Yokote, M.D., Ph.D., Niels Zeuthen, M.Sc., and Robert F. Kushner, M.D., for the STEP 1 Study Group*
Obesity is a global health challenge with few pharmacologic options. Whether adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 mg as an adjunct to lifestyle intervention has not been confirmed.